C OSBORNE to Mitoxantrone
This is a "connection" page, showing publications C OSBORNE has written about Mitoxantrone.
Connection Strength
0.154
-
Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst. 1991 Aug 07; 83(15):1077-84.
Score: 0.089
-
Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study. Eur J Cancer. 1992; 28(2-3):477-8.
Score: 0.023
-
Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. Cancer Treat Rep. 1983 Dec; 67(12):1133-5.
Score: 0.013
-
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol. 1999 Oct; 17(10):3058-63.
Score: 0.010
-
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res. 1997 Apr; 3(4):593-600.
Score: 0.008
-
Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer. A Southwest Oncology Group study. Invest New Drugs. 1994; 12(2):129-32.
Score: 0.007
-
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). Invest New Drugs. 1985; 3(2):149-52.
Score: 0.004